Utilizing Everolimus and Sunitinib in pNETs OncLive In May 2011, the FDA approved sunitinib (Sutent) for the treatment of progressive well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable, locally advanced, or metastatic disease. In the pivotal study that led to the ... |
